AstraZeneca
Global biopharmaceutical company focused on discovery, development and delivery of medicines across oncology, biopharmaceuticals (cardiovascular, renal & metabolism, respiratory & immunology, infectious disease) and rare disease. The organisation develops next-generation therapeutics (gene and cell therapies), integrates large-scale genomics and AI into R&D, operates global clinical development and manufacturing centres, and partners with academia, start-ups and industry to advance translational science.
Industries
Nr. of Employees
Very Large (1000+)
AstraZeneca
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
Open-access genomics and AI research platforms
Publicly accessible platforms for population-scale genomics analysis, phenotype-wide association exploration, ML-based disease prediction and gene triaging using knowledge-graph approaches.
SEROQUEL (quetiapine) tablets
Tablets containing quetiapine.
SEROQUEL XR (quetiapine) Extended-release tablets
Extended-release tablets containing quetiapine.
ENHERTU (fam-trastuzumab deruxtecan-nxki) injection for intravenous use
Injection containing fam-trastuzumab deruxtecan-nxki for intravenous use.
FASENRA
Benralizumab solution for injection for subcutaneous injection from a single-dose pre-filled syringe, indicated for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
DALIRESP (roflumilast) tablets
Tablets containing roflumilast.
Open-access genomics and AI research platforms
Publicly accessible platforms for population-scale genomics analysis, phenotype-wide association exploration, ML-based disease prediction and gene triaging using knowledge-graph approaches.
SEROQUEL (quetiapine) tablets
Tablets containing quetiapine.
SEROQUEL XR (quetiapine) Extended-release tablets
Extended-release tablets containing quetiapine.
ENHERTU (fam-trastuzumab deruxtecan-nxki) injection for intravenous use
Injection containing fam-trastuzumab deruxtecan-nxki for intravenous use.
FASENRA
Benralizumab solution for injection for subcutaneous injection from a single-dose pre-filled syringe, indicated for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
DALIRESP (roflumilast) tablets
Tablets containing roflumilast.
Services
Mentoring connecting start-ups and academic teams with internal scientific and commercial experts to advise on early science, technology transfer and commercialisation.
Partnerships with academic centres, consortia and industry to co-develop discovery technologies, share datasets and accelerate translational research.
Mentoring connecting start-ups and academic teams with internal scientific and commercial experts to advise on early science, technology transfer and commercialisation.
Partnerships with academic centres, consortia and industry to co-develop discovery technologies, share datasets and accelerate translational research.
Expertise Areas
- Cell and gene therapy development
- Oligonucleotide therapeutics and targeted delivery
- Oncology R&D and translational research
- Population genomics and multi-omics integration
Key Technologies
- CRISPR and functional genomics screening
- Antisense and siRNA oligonucleotide platforms
- Tissue-targeting ligand conjugates for delivery
- Lipid nanoparticle delivery and controlled-release formulations
News & Updates
Publication reporting a machine-learning model for non-invasive prediction of hepatic decompensation in chronic liver disease.
Reported portfolio of 183 projects in the clinical and preclinical pipeline.
Reported investment of $14.2 billion in R&D for 2025.
Maintains a population-scale genomic dataset of more than 1.7 million genomes with matched clinical insights.
Publication reporting a machine-learning model for non-invasive prediction of hepatic decompensation in chronic liver disease.
Reported portfolio of 183 projects in the clinical and preclinical pipeline.
Reported investment of $14.2 billion in R&D for 2025.
Maintains a population-scale genomic dataset of more than 1.7 million genomes with matched clinical insights.